Codevax Inc. has a unique relationship with the University of Rochester Medical Center. Our innovative business model is designed to accelerate vaccine development by utilizing capabilities and assets of both parties to overcome barriers that sometimes occur in the transfer of academic technology to the private sector. This special relationship allows Codevax access to the scientific expertise of world-class URMC scientists, as well as a "first look" at intellectual property owned by the University in vaccine-related research areas that relate to Codevax's interests, and flexibility in negotiation of licensing and option arrangements that provide access to these technologies.
HibTITER®:
The first vaccine for Haemophilus influenza type b (Hib), which is responsible for nearly all cases of childhood meningitis, was developed by URscientists, led by Drs. David H. Smith and Porter Anderson. This vaccine has reduced the incidence of bacterial meningitis by 98%. Drs. Smith and Anderson were awarded the 1996 Albert Lasker Clinical Medical Research Award for this outstanding achievement.
Prevnar®:
Using the same technology behind the Hib conjugate vaccine, Dr. Anderson created a means to vaccinate against the Streptococcus pnuemoniaebacterium. Introduced in 1990, this vaccine provides 98% immunity to invasive infections by the seven most common serotypes of S. pneumoniae, which are responsible for pneumonia, meningitis, and other serious infections.
Read More
Cervical Cancer (Human Papillomavirus) vaccines:
Early-stage development of vaccines to prevent cervical cancer occurred at the University of Rochester. URscientists Robert Rose, William Bonnez, and Richard Reichman developed a critical technology that led to the production of vaccines designed to prevent infection with the human papillomavirus (HPV), the leading cause of cervical cancer. Vaccines are now available world-wide and could save hundreds of thousands of lives every year.
Center for Musculoskeletal ResearchURMC has a distinguished history of musculoskeletal research.
The Center for Musculoskeletal Research was created in 2000, and is directed by Dr. Regis O' Keefe. This interdisciplinary center includes investigators with broad scientific expertise and includes a NIH-funded Center of Research Translation (CORT). The Center is currently the top ranked orthopaedics program in the country, and features comprehensive research programs. These include an emphasis on bone disease, and infections of bone - such as Methicillin Resistant Staphylococcus Aureus (MRSA).
Read More
The University of Rochester Clinical and Translational Science Institute is a national leader in the expanding field of clinical and translational research. The Institute is building the foundation to assist researchers at the University of Rochester and across Upstate New York to produce innovative technology and methods that more efficiently and more quickly advance treatments to patients. Recently, URMC opened its new $76 million Saunders Research Building, that will serve as a central hub for the resources, expertise, and networks necessary to fast-track biomedical research into real-word cures.
Read More
The URMC Strategic Plan represents a $500 million growth plan, intended to build on the research strengths of the Medical Center. At the heart of this plan are five Integrated Disease Programs that focus research, teaching, and patient care services on the conditions that plague large segments of our population. Key among these programs is the Immunology and Infectious Diseases program. This program seeks to develop a nationally recognized patient-based human immunology research program focused on vaccine responses.
Read More
The David H. Smith Center for Vaccine Biology and Immunology (CBVI) was formed at URMC in 1998, and is directed by Dr. Tim Mosmann. Research in the Center is focused on basic research into immunological mechanisms with a long time goal of helping to design the next generation of vaccines.
Read More
The NYICE is a collaborative, interdisciplinary center involving
investigators in the fields of immunology, virology, biochemistry, medicine, pediatrics, statistics and bioinformatics, directed by Dr. John Treanor. Its focus is on cross-protective immunity to influenza and virus adaptation to the mammalian host. The NYICE is one of 5 national centers that are part of the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) program.
Read More
The University of Rochester has broad institutional strengths in many areas of research that relate to vaccine development.
Read More